Radiopharm Theranostics Ltd (RAD) — Cash Flow-to-Debt Ratio
Radiopharm Theranostics Ltd (RAD) has a Cash Flow-to-Debt Ratio of -0.55x as of December 2025, meaning its operating cash flow of AU$-22.67 Million could theoretically repay -1% of its total liabilities (AU$41.23 Million) in one year. See RAD working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Radiopharm Theranostics Ltd Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Radiopharm Theranostics Ltd across 5 annual periods. Also explore RAD shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Radiopharm Theranostics Ltd (2021–2025)
Year-by-year debt coverage analysis for Radiopharm Theranostics Ltd. For market capitalisation and broader financial context, see market value of Radiopharm Theranostics Ltd.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.84x | AU$-36.65 Million | AU$43.61 Million | ▼ -63.4% |
| 2024 | -0.51x | AU$-22.98 Million | AU$44.68 Million | ▲ +34.9% |
| 2023 | -0.79x | AU$-23.20 Million | AU$29.37 Million | ▼ -62.8% |
| 2022 | -0.49x | AU$-9.91 Million | AU$20.42 Million | ▼ -133.2% |
| 2021 | -0.21x | AU$-32.91K | AU$158.14K | — |